A5033680007- Liver Disease Diagnosis and Treatment
- Liver physiology and pathology
- Drug Transport and Resistance Mechanisms
- Liver Diseases and Immunity
- Helicobacter pylori-related gastroenterology studies
- Drug-Induced Hepatotoxicity and Protection
- Silymarin and Mushroom Poisoning
China Pharmaceutical University
2018-2021
State Key Laboratory of Natural Medicine
2018
Farnesoid X receptor (FXR) is a promising target for nonalcoholic steatohepatitis (NASH) and fibrosis. Although various FXR agonists have shown anti-fibrotic effects in diverse preclinical animal models, the response rate efficacies clinical trials were not optimum. Here we report that prophylactic but therapeutic administration of obeticholic acid (OCA) prevents hepatic stellate cell (HSC) activation fibrogenesis. Activated HSCs show limited to OCA other due enhanced SUMOylation....
Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be against fibrosis, possibly due to lower dosage reduce incidence side-effect pruritus. Here we propose a combinatory therapeutic strategy and apoptosis inhibitor for combating CCl